ஹைதராபாத் அடிப்படையிலானது நாட்கோ பார்மா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Indian Pharma on a Profit Trip(S)
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Big Pharma and intellectual property: Why is India afraid of compulsory licences?
downtoearth.org.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from downtoearth.org.in Daily Mail and Mail on Sunday newspapers.
US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in a statement. The firm added that discussions were also taking place with other Indian players for the grant of voluntary licences to manufacture Baricitinib, which has recently found favour among clinicians for the treatment of Covid-19.
Hyderabad/Mumbai: In the first instance of a pharma company taking the compulsory licensing (CL) route to launch a Covid drug in India, Hyderabad-based Natco Pharma has filed for a waiver of patent rights to manufacture rheumatoid arthritis drug Baricitinib. The CL, if granted, will help in improving the accessibility and affordability of the drug, bringing its price down substantially.
The USFDA had last November granted emergency authorisation for Baricitinib in combination with Remdesivir.
At present, a limited quantity of the patented drug is available in the country, and that too, at an exorbitant price (see graphic). The patent is held by Incyte Holdings, with a licence to Eli Lilly, which markets the drug under the Olumiant brand name. The application has been filed under Section 92 of the Patents Act, which can be invoked by the Centre due to a national emergency, circumstances of extreme urgency or in case of public non-commercial use.
Natco Pharma shares rose as much as 4.27%
Shares of the Hyderabad-based Natco Pharma gained as much as 4.27 per cent to hit an intraday high of Rs 935 after it received emergency use approval for drug to treat COVID-19 positive patients. Natco Pharma Limited has received emergency use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients, the company said in a press release.
COVID-19 drugs like Remdesivir are in huge shortage owing to rising number of Covid-19 infections in the country. On Monday, India s active caseload passed the 34 lakh-mark with 3,68,147 fresh infections added in the last 24 hours, six per cent lower than yesterday s spike. Over 3,417 Covid-linked deaths have been reported since yesterday, taking total deaths to 2,18,959.
vimarsana © 2020. All Rights Reserved.